New study: does starting this pill sooner save colitis patients from surgery?
NCT ID NCT07472309
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked back at medical records of 81 people with severe ulcerative colitis to see if starting upadacitinib early works better than using it after other treatments fail. Researchers checked how many avoided surgery and achieved remission within 12 weeks. The goal is to find the best timing for this medication in real-world care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
upadacitinib (a pill that reduces inflammation)
What this could lead to
If successful, this could show that using upadacitinib early is better than waiting until other treatments fail, potentially reducing the need for surgery.
What could go wrong
This is a small, retrospective study (not a controlled trial), so results may not apply to everyone. Upadacitinib can have side effects like infections or blood clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xijing Hospital,Fourth Military Medical University
Xi'an, Shaanxi, 710032, China